Missouri is currently home to 1899 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Saint Louis, Kansas City, St. Louis and Springfield. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of CNP-106 in Subjects with Myasthenia Gravis
NCT06106672
Recruiting
Phase 1b/2a First-in-Human (FIH) clinical trial to assess the safety, tolerability, pharmacodynamics (PD), and efficacy of multiple ascending doses of CNP-106.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
02/12/2025
Locations: University of Missouri, NextGen Precision Health, Columbia, Missouri
Conditions: Myasthenia Gravis, Generalized Myasthenia, AChR Myasthenia Gravis, MuSK MG
Register for Updates
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
NCT04094610
Recruiting
Phase 1 will evaluate the safety and tolerability at different dose levels of repotrectinib in pediatric and young adult subjects with advanced or metastatic malignancies harboring anaplastic lymphoma kinase (ALK), receptor tyrosine kinase encoded by the gene ROS1 (ROS1), or neurotrophic receptor kinase genes encoding TRK kinase family (NTRK1-3) alterations to estimate the Maximum Tolerated Dose (MTD) or Maximum Administered Dose (MAD) and select the Pediatric Recommended Phase 2 Dose (RP2D). P... Read More
Gender:
ALL
Ages:
25 years and below
Trial Updated:
02/12/2025
Locations: Washington University School of Medicine in St. Louis, Saint Louis, Missouri
Conditions: Locally Advanced Solid Tumors, Metastatic Solid Tumors, Lymphoma, Primary CNS Tumors
Register for Updates
Generic Database of Very Low Birth Weight Infants
NCT00063063
Recruiting
The Generic Database (GDB) is a registry of very low birth weight infants born alive in NICHD Neonatal Research Network (NRN) centers. The GDB collects observational baseline data on both mothers and infants, and the therapies used and outcomes of the infants. The information collected is not specific to a disease or treatment (i.e., it is "generic"). Data are analyzed to find associations and trends between baseline information, treatments, and infant outcome, and to develop future NRN trials.
Gender:
ALL
Ages:
14 days and below
Trial Updated:
02/11/2025
Locations: Children's Mercy Hospital, Kansas City, Missouri
Conditions: Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature
Register for Updates
Follow-up Visit of High Risk Infants
NCT00009633
Recruiting
The NICHD Neonatal Research Network's Follow-Up study is a multi-center cohort in which surviving extremely low birth-weight infants born in participating network centers receive neurodevelopmental, neurosensory and functional assessments at 22-26 months corrected age (Infants born prior to July 1, 2012 were seen at 18-22 months corrected age). Data regarding pregnancy and neonatal outcome are collected prospectively. The goal is to identify potential maternal and neonatal risk factors that may... Read More
Gender:
ALL
Ages:
Between 18 months and 26 months
Trial Updated:
02/11/2025
Locations: Children's Mercy Hospital, Kansas City, Missouri
Conditions: Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature
Register for Updates
Vertebral Artery Origin Treatment Via Endovascular Techniques Registry (VOTER)
NCT03999983
Recruiting
A retrospective and prospective registry of patients admitted for stroke and evidence of Vertebral Artery Origin Stenosis (VAOS).
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
02/10/2025
Locations: SSM DePaul Hospital, Bridgeton, Missouri
Conditions: Vertebral Artery Stenosis
Register for Updates
A Study of AK117 in Combination With Azacitidine in Patients With Myelodysplastic Syndromes
NCT06196203
Recruiting
This is a Phase 2 randomized, double-blind, placebo-controlled, multicenter study evaluating the efficacy and safety of AK117 or placebo, combined with azacitidine in patients with newly diagnosed higher-risk myelodysplastic syndromes (HR-MDS).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/09/2025
Locations: Washington University School of Medicine in St. Louis, Saint Louis, Missouri
Conditions: Higher-risk Myelodysplastic Syndromes
Register for Updates
Study to Understand Novel Biomarkers in Researching Dementia
NCT06547099
Recruiting
The purpose of this study is to determine the relationships between amyloid, tau, and neurodegeneration biomarkers in the blood and the presence of Alzheimer's disease (AD) pathology, clinical cognitive decline, and diagnosis. We aim to understand how well blood-based biomarkers can diagnose and predict Alzheimer's disease, which will help to further develop and validate blood tests for the disease.
Gender:
ALL
Ages:
60 years and above
Trial Updated:
02/07/2025
Locations: Washington University School of Medicine, Saint Louis, Missouri
Conditions: Alzheimer Disease, Mild Cognitive Impairment, Dementia
Register for Updates
Low Field Magnetic Resonance Imaging Assessment with Outpatients
NCT05582785
Recruiting
The objective of the study is to perform imaging assessments of an early stage magnetic resonance imaging (MRI) system on patients using low field magnetic strength.
Gender:
ALL
Ages:
Between 0 years and 22 years
Trial Updated:
02/07/2025
Locations: Children's Mercy Kansas City, Kansas City, Missouri
Conditions: Conditions Requiring a Brain Magnetic Resonance Imaging, Head Computerized Tomography, or Head Ultrasound
Register for Updates
Low Field and High Field Magnetic Resonance Imaging Assessments on Pediatric Patients
NCT04629469
Recruiting
Hyperfine Research, Inc. has taken advantage of technological advances and developed an MRI device that is not only portable, but also uses a very-low magnetic field strength, \[less than 0.2 Tesla or approximately 10 times less\] than the field strength of conventional devices. This critical difference allows HRI to address MRI's core challenges by, first, operating at very low magnetic field strengths, eliminating the need for special rooms or shielding. Second, there are minimal safety concer... Read More
Gender:
ALL
Ages:
Between 0 days and 22 years
Trial Updated:
02/07/2025
Locations: Children's Mercy Hospital, Kansas City, Missouri
Conditions: Conditions Requiring a Brain Magnetic Resonance Imaging, Head Computerized Tomography, or Head Ultrasound
Register for Updates
Maternal Oxygen Supplementation for Intrauterine Resuscitation
NCT05681624
Recruiting
More than 80% of the 3 million women who labor and deliver each year in the United States undergo continuous electronic fetal monitoring (EFM) during labor in order to fetal hypoxia and prevent the transition to acidemia, expedited operative delivery, and/or neonatal morbidity. Category II EFM is the most commonly observed group of fetal heart rate features in labor. One common response to Category II EFM is maternal oxygen (O2) supplementation. The theoretic rationale for O2 administration is t... Read More
Gender:
FEMALE
Ages:
All
Trial Updated:
02/06/2025
Locations: Barnes Jewish Hospital, Saint Louis, Missouri
Conditions: Fetal Distress, Fetal Hypoxia, Labor and Delivery Complication
Register for Updates
PROACTIVE-HF-2 Trial Heart Failure NYHA Class II and III
NCT05934487
Recruiting
This is a prospective, multi-center, open label, randomized control clinical trial evaluating the safety and efficacy of the Cordella™ Pulmonary Artery Sensor System in NYHA Class II-III Heart Failure Patients (PROACTIVE-HF-2 Trial). The study contains of 5 arms: NYHA II Cohort - To demonstrate safety and efficacy of the Cordella PA Sensor System in NYHA Class II HF patients, where patients have daily access to PAP data. * Treatment Arm (Group 1) * Active Control Arm (Group 2) * Crossover Arm... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/05/2025
Locations: St. Lukes/ Mid-American Heart Institute, Kansas City, Missouri
Conditions: Heart Failure NYHA Class II, Heart Failure NYHA Class III, Heart Failure
Register for Updates
Liver Adiposity Effects on Pediatric Statin
NCT04903223
Recruiting
Single center, open-label, prospective investigation to quantify the effects hepatocellular fat has on hepatic statin transport and response in children and adolescents in obese and non-obese children and adolescents 8-21 years of age with normal, wild-type SLCO1B1 c.521TT genotype that are dosed rosuvastatin
Gender:
ALL
Ages:
Between 8 years and 21 years
Trial Updated:
02/05/2025
Locations: Children's Mercy Hospital, Kansas City, Missouri
Conditions: Cholesterol; Lipidosis
Register for Updates